PURPOSE: The influence of microenvironmental factors on the effectiveness of chemotherapy is being increasingly recognized. The purpose of this study was to investigate the relationships between cancer cell and stromal cell phenotypes in primary tumors and the progression-free survival (PFS) of recurrent lung cancer patients who received platinum-based chemotherapy. METHODS: We retrospectively analyzed 87 postoperative recurrent lung adenocarcinoma patients treated with platinum-based chemotherapy. The expressions of drug resistance-related proteins including BCRP, ezrin, and ALDH1 in cancer cells, the number of CD204-positive tumor-associated macrophages (TAMs), and the presence of podoplanin-positive cancer-associated fibroblasts (CAFs) in the primary tumor were examined. The relationships between the immunohistochemical staining results of primary tumors and the PFS after receiving chemotherapy were also analyzed. RESULTS: Among the clinicopathological factors of primary tumors, only an advanced pathological stage was significantly associated with a shorter PFS. As for immunohistochemical staining, no significant relationships were found between the PFS and the expression of BCRP, ezrin, or ALDH1. Although the number of CD204-positive TAMs was not associated with the PFS, the presence of podoplanin-positive CAFs was significantly associated with a shorter PFS (median PFS: 5.1 vs. 7.8 months, P = 0.028). A multivariate analysis revealed a tendency of podoplanin-positive CAFs to be correlated with a shorter PFS (P = 0.087). CONCLUSIONS: The presence of podoplanin-positive CAFs in the primary tumor could be a predictor of a shorter PFS in recurrent lung adenocarcinoma patients who received chemotherapy. These findings suggest that stromal-cell-derived factors should be incorporated into predictions of the effectiveness of chemotherapy.
PURPOSE: The influence of microenvironmental factors on the effectiveness of chemotherapy is being increasingly recognized. The purpose of this study was to investigate the relationships between cancer cell and stromal cell phenotypes in primary tumors and the progression-free survival (PFS) of recurrent lung cancerpatients who received platinum-based chemotherapy. METHODS: We retrospectively analyzed 87 postoperative recurrent lung adenocarcinomapatients treated with platinum-based chemotherapy. The expressions of drug resistance-related proteins including BCRP, ezrin, and ALDH1 in cancer cells, the number of CD204-positive tumor-associated macrophages (TAMs), and the presence of podoplanin-positive cancer-associated fibroblasts (CAFs) in the primary tumor were examined. The relationships between the immunohistochemical staining results of primary tumors and the PFS after receiving chemotherapy were also analyzed. RESULTS: Among the clinicopathological factors of primary tumors, only an advanced pathological stage was significantly associated with a shorter PFS. As for immunohistochemical staining, no significant relationships were found between the PFS and the expression of BCRP, ezrin, or ALDH1. Although the number of CD204-positive TAMs was not associated with the PFS, the presence of podoplanin-positive CAFs was significantly associated with a shorter PFS (median PFS: 5.1 vs. 7.8 months, P = 0.028). A multivariate analysis revealed a tendency of podoplanin-positive CAFs to be correlated with a shorter PFS (P = 0.087). CONCLUSIONS: The presence of podoplanin-positive CAFs in the primary tumor could be a predictor of a shorter PFS in recurrent lung adenocarcinomapatients who received chemotherapy. These findings suggest that stromal-cell-derived factors should be incorporated into predictions of the effectiveness of chemotherapy.
Authors: J A Ajani; X Wang; S Song; A Suzuki; T Taketa; K Sudo; R Wadhwa; W L Hofstetter; R Komaki; D M Maru; J H Lee; M S Bhutani; B Weston; V Baladandayuthapani; Y Yao; S Honjo; A W Scott; H D Skinner; R L Johnson; D Berry Journal: Mol Oncol Date: 2013-10-28 Impact factor: 6.603
Authors: Sophie Le Guellec; Elizabeth Cohen-Jonathan Moyal; Thomas Filleron; Marie-Bernadette Delisle; Christine Chevreau; Hervé Rubie; Marie-Pierre Castex; Jerome Sales de Gauzy; Paul Bonnevialle; Anne Gomez-Brouchet Journal: Hum Pathol Date: 2013-07-08 Impact factor: 3.466
Authors: Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades Journal: Nat Med Date: 2010-03-14 Impact factor: 53.440
Authors: Thomas K Kilvaer; Mehrdad Rakaee Khanehkenari; Turid Hellevik; Samer Al-Saad; Erna-Elise Paulsen; Roy M Bremnes; Lill-Tove Busund; Tom Donnem; Inigo Z Martinez Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240
Authors: Mark J Schliekelman; Chad J Creighton; Brandi N Baird; Yulong Chen; Priyam Banerjee; Neus Bota-Rabassedas; Young-Ho Ahn; Jonathon D Roybal; Fengju Chen; Yiqun Zhang; Dhruva K Mishra; Min P Kim; Xin Liu; Barbara Mino; Pamela Villalobos; Jaime Rodriguez-Canales; Carmen Behrens; Ignacio I Wistuba; Samir M Hanash; Jonathan M Kurie Journal: Sci Rep Date: 2017-07-25 Impact factor: 4.379
Authors: Kit Yee Wong; Alvin Ho-Kwan Cheung; Bonan Chen; Wai Nok Chan; Jun Yu; Kwok Wai Lo; Wei Kang; Ka Fai To Journal: Int J Cancer Date: 2022-06-08 Impact factor: 7.316
Authors: Thomas Karsten Kilvaer; Mehrdad Rakaee; Turid Hellevik; Arne Østman; Carina Strell; Roy M Bremnes; Lill-Tove Busund; Tom Dønnem; Inigo Martinez-Zubiaurre Journal: PLoS One Date: 2018-02-07 Impact factor: 3.240